+Vote!
JJS Diabetes (Free subscription) | 22/10/2008
A study out of the University of Granada in Spain suggests further evaluation of interleukin-6 as a diabetes therapy may be worthwhile. Dr. Jose Luis Mesa, one of the main authors of the study, together with scientists of the University of Melbourne and the Baker Heart Research Institute, both in Australia, collaborated with the company Vitagenes to find that the exogenous administration...
+Vote!
Times of the Internet (Free subscription) | 21/10/2008
GRANADA, Spain, Oct. 20 (UPI) -- University of Granada researchers in Spain say a molecule called interleukin-6 has opened new doors for new drugs against obesity and diabetes. Dr. Jose Luis Mesa, one of the main authors of the study, together with scientists of the University of Melbourne and the Baker Heart Research Institute, both in Australia, collaborated with the company Vitagenes...
+Vote!
Later On (Free subscription) | 20/10/2008
... (PTS). Vitagenes has collaborated in this project through its technical director, doctor José Luis Mesa , who has been one of the main authors of the study together with distinguished scientists of the University of Melbourne and the Baker Heart Research Institute (Australia). The most relevant results of the project, such as a potential treatment to prevent diabetes and obesity,...
+Vote!
Red Orbit (Free subscription) | 21/10/2008
Dr. Jose Luis Mesa, one of the main authors of the study, together with scientists of the University of Melbourne and the Baker Heart Research Institute, both in Australia, collaborated with the company Vitagenes to find that the exogenous administration of interleukin-6 improved insulin sensitivity and the absorption of glucose -- essential for diabetics.
